Last reviewed · How we verify
sIPV-bOPV-bOPV vaccination schedule
The sIPV-bOPV-bOPV vaccine stimulates the body's immune system to produce antibodies against poliovirus and rotavirus.
The sIPV-bOPV-bOPV vaccine stimulates the body's immune system to produce antibodies against poliovirus and rotavirus. Used for Prevention of poliomyelitis and rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | sIPV-bOPV-bOPV vaccination schedule |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing inactivated poliovirus and rotavirus antigens to the body, which triggers an immune response and helps to prevent future infections.
Approved indications
- Prevention of poliomyelitis and rotavirus gastroenteritis in infants and young children
Common side effects
- Injection site pain
- Fever
- Vomiting
Key clinical trials
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV (PHASE3)
- To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV (PHASE4)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants (PHASE3)
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sIPV-bOPV-bOPV vaccination schedule CI brief — competitive landscape report
- sIPV-bOPV-bOPV vaccination schedule updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI